BioWin presents feasibility analysis report of a vaccine trial network at BioWin Days

Belgium has long been recognised as a global leader in vaccine trials, thanks to world-class expertise, strong centres of excellence and a highly integrated supply chain. Yet, this leadership is now under pressure.

At the upcoming BioWin Days, BioWin will unveil the results of a feasibility analysis on a federal vaccine trial network, carried out in collaboration with Deloitte. The study identifies the barriers holding Belgium back, such as regulatory delays under the EU Clinical Trials Regulation, challenges in volunteer recruitment, regional imbalances in capacity, shortages of trained staff, fragmented data systems and limited dedicated infrastructure.

At the same time, the analysis highlights a unique opportunity: by connecting centres of excellence with emerging sites across regions, and investing in coordination, training, data, and community engagement, Belgium can reassert itself as one of Europe’s most attractive locations for vaccine R&D.

To explore these findings, a dedicated panel at BioWin Days will bring together leading voices: a representative from the European Plotkin Institute for Vaccinology, Laurence Vigneron (AFMPS), Benjamin Boinem (InoKura – CHU Liège), Cristel Noirhomme (GSK), and Thibault Helleputte (DNAlytics). Together, they will tackle the key challenges and opportunities for Belgium’s vaccine trial ecosystem.

The goal: to set the foundations for a federal network that strengthens Belgium’s competitiveness and ensures it remains at the forefront of global vaccine research.